LTIP 및 공유 옵션 체계
주식선택권 부여 및 장기 인센티브 제도에 따른 포상
Hong Kong, Shanghai, & Florham Park, NJ: Thursday14 년 2024 월 XNUMX 일 : HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces that on March 14, 2024, it granted share options ("Share Options") under the Share Option Scheme adopted by HUTCHMED in 2015 (the "Share Option Scheme") and awards ("LTIP Awards") under the Long Term Incentive Plan adopted by HUTCHMED in 2015 ("LTIP").
Aimed at attracting and retaining top talent, the Remuneration Committee of HUTCHMED appointed an independent advisor to conduct compensation benchmarking research on a selected peer group of companies. As a result of this the Remuneration Committee has comprehensively reviewed the compensation and share-based incentives policies of HUTCHMED and its subsidiaries (the "Group") and established an attractive policy to ensure the Group is able to recruit and retain top talent. In line with this review HUTCHMED has decided to make the following grant of Share Options and LTIP Awards.
1. Performance Related Share Options
HUTCHMED granted Share Options subject to the Performance Targets (defined below) under its Share Option Scheme to Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer), being a person discharging managerial responsibility ("PDMR") under the UK Market Abuse Regulation to subscribe for a total of 1,359,561 ordinary shares with par value US$0.10 each in the share capital of the Company ("Ordinary Shares") subject to the acceptance of the grantee. Details of such Share Options granted are as follows:
부여일 | : | 2024 년 3 월 13 일
|
부여된 주식선택권의 행사가격 | : | HK$28.35 per Ordinary Share
|
부여된 주식선택권 수 | : | 보통주 1,359,561주
|
부여일의 HKEX에서 보통주의 마감 시장 가격
| : | HK$28.35 per Ordinary Share
|
Exercise period of the share options | : | 13 년 2024 월 12 일 ~ 2034 년 XNUMX 월 XNUMX 일
|
주식선택권의 가득기간 | : | Vesting will occur two business days after the date of announcement of the annual results of the Company for the financial year ending December 31, 2025 (the "2025 Results Announcement").
|
성능 목표 | : | The exercise of the share options is conditional upon the fulfilment of certain performance targets relating to the Group over the financial years 2023 to 2025 (the "Performance Targets"). The number of share options to be exercisable will be determined on the date of 2025 Results Announcement. The Performance Targets have been determined by the Board and specified in the grant letter of Dr Su. To the extent that the Performance Targets have not been met, the relevant number of share options granted to Dr Su will lapse.
|
Clawback mechanism | : | The share options may be subject to the clawback policy of the Company enabling the Company to recover incentive-based compensation paid to covered executive officers in the event of mis-statement of the financial statements of the Company resulting from material non-compliance with financial reporting requirements. |
After the above grant of Share Options, the number of Share Options available for future grant under the scheme mandate of the Share Option Scheme is 11,678,982.
2. Non-performance-related LTIP Award ("Non-performance LTIP Award") - a one-off cash amount was granted to each grantee and will be used by the trustee administering the LTIP (the "Trustee") to purchase Ordinary Shares in HUTCHMED which will be subject to a vesting schedule over four years. HUTCHMED granted the following Non-performance LTIP Awards to the following Executive Director, being a PDMR under the UK Market Abuse Regulation:
수상자 |
| Cash amount for the Non- Performance LTIP Awards |
|
|
|
Weiguo Su 박사(전무이사, 최고경영자 겸 최고과학책임자) |
| US $ 500,000 |
The non-performance-related LTIP Award was granted to Dr Su in recognition of his contribution to the Company in his dual role as Chief Executive Officer and Chief Scientific Officer.
Another employee of the Group has simultaneously been granted non-performance related LTIP Awards.
The notification in respect of share options granted to Dr Su in accordance with the requirements of the UK Market Abuse Regulation is set out below.
Weiguo Su 박사
1 | 관리 책임을 다하는 사람 / 연계 인의 내용 | |||||||
a) |
성함 |
Weiguo Su 박사
| ||||||
2 | 신고 사유 | |||||||
a) |
직위/상태 |
전무 이사, 최고 경영자 및 최고 과학 책임자
| ||||||
b) |
최초 고시/수정
|
초기 알림
| ||||||
3 | 발행자, 배출 허용량 시장 참가자, 경매 플랫폼, 경매 인 또는 경매 모니터에 대한 세부 정보 | |||||||
a) |
성함
|
HUTCHMED(중국) 제한 | ||||||
b)
|
법 |
2138006X34YDQ6OBYE79 | ||||||
4 | 거래의 세부 사항 : (i) 각 유형의 상품에 대해 반복되는 섹션; (ii) 각 유형의 거래; (iii) 각 날짜; 및 (iv) 거래가 수행 된 각 장소 | |||||||
a) |
금융 상품 설명, 상품 유형
식별 코드 |
Share option over Ordinary Shares of US$0.10
Share option over Ordinary Share with DI ISIN: KYG4672N1016 | ||||||
b) |
거래의 성격
|
Grant of options in respect of 1,359,561 Ordinary Shares under the Share Option Scheme.
The exercise of the share options is conditional upon the fulfilment of certain performance targets relating to the Group over the financial years 2023 to 2025 (the "Performance Targets"). The number of share options to be exercisable will be determined on the date of 2025 Results Announcement. The Performance Targets have been determined by the Board and specified in the grant letter of Dr Su. To the extent that the Performance Targets have not been met, the relevant number of share options granted to Dr Su will lapse.
| ||||||
c) |
가격 및 수량 |
| ||||||
d) |
집계 된 정보
|
해당 사항 없음 | ||||||
e) |
거래 날짜 |
2024-3-13
| ||||||
f) |
거래 장소 |
거래 장소 외부
|
HUTCHMED 정보
HUTCHMED (Nasdaq/AIM:?HCM; HKEX:?13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/?immunology. Since inception, it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S.. For more information, please visit: www.hutch?med.com or follow us on LinkedIn.
앞으로-보고 진술
이 발표는 1995년 미국 증권민사소송개혁법(US Private Securities Litigation Reform Act)의 "세이프 하버" 조항의 의미 내에서 미래예측 진술을 포함하고 있습니다. 미래예측 진술에는 위험과 불확실성이 내포되어 있습니다. 기존 및 장래의 투자자는 본 문서의 날짜 현재에만 해당하는 이러한 미래 예측 진술에 과도하게 의존하지 않도록 주의해야 합니다. 이러한 위험 및 기타 위험에 대한 추가 논의는 AIM 및 HKEX에 대한 HUTCHMED가 미국 증권 거래 위원회에 제출한 문서를 참조하십시오. HUTCHMED는 새로운 정보, 미래의 사건 또는 상황 등의 결과로 인해 이 발표에 포함된 정보를 업데이트하거나 수정할 의무가 없습니다.
연락처
투자자 문의 | +852 2121 8200 / [이메일 보호] |
미디어 문의 |
|
벤 앳웰 / 알렉스 쇼, FTI 컨설팅 | +44 20 3727 1030 / +44 7771 913 902 (이동하는) / +44 7779 545 055 (모바일) | [이메일 보호] |
저우이, 브런 즈윅 | +852 9783 6894 (변하기 쉬운) |
후보 고문 | |
Atholl Tweedie / Freddy Crossley / Daphne Zhang, 판뮤어 고든 | +44 (20) 7886 2500 |
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.